Clinical Trials Logo

Clinical Trial Summary

Cognitive impairment affects up to 65% of multiple sclerosis (MS) subjects, especially memory function.

Rothschild Foundation has developped the Paris Visual Learning and memory Test (PVLT). 165 healthy volunteers were studied for its normalization.

The main objective of the present study is to assess the validity of PVLT by comparing MS patients' test results to a database including the test results of 280 healthy control subjects, following recommended international standards.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT02893683
Study type Observational
Source Fondation Ophtalmologique Adolphe de Rothschild
Status Completed
Phase N/A
Start date December 19, 2013
Completion date May 15, 2017

See also
  Status Clinical Trial Phase
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Active, not recruiting NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Recruiting NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Not yet recruiting NCT03550170 - Fatigue Management Programs for People With MS N/A
Active, not recruiting NCT03711968 - Interoception and Sense of Movement in the Patient With Multiple Sclerosis N/A
Recruiting NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4
Recruiting NCT02232061 - Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod Phase 4
Recruiting NCT03122652 - Multi-center, Interventional, Phase 3, Randomized, Double-blinded Study of Treatment:Teriflunomide®, in Radiologically Isolated Syndrome Phase 3
Recruiting NCT03326505 - Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment Phase 1/Phase 2
Recruiting NCT03424733 - Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects Phase 4
Recruiting NCT03396822 - Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
Recruiting NCT03355365 - Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis Phase 2
Not yet recruiting NCT03607773 - Mindfulness for Newly Diagnosed Multiple Sclerosis N/A
Recruiting NCT02939859 - Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions N/A
Completed NCT02898974 - Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis N/A
Recruiting NCT02283671 - Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Phase 1
Active, not recruiting NCT02522962 - Innovative Physiotherapy and Coordination of Care for People With MS: a RCT and a Qualitative Study N/A